Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Polo-Like Kinase 1 phosphorylates and stabilizes KLF4 to promote tumorigenesis in nasopharyngeal carcinoma.

Mai J, Zhong ZY, Guo GF, Chen XX, Xiang YQ, Li X, Zhang HL, Chen YH, Xu XL, Wu RY, Yu Y, Li ZL, Peng XD, Huang Y, Zhou LH, Feng GK, Guo X, Deng R, Zhu XF.

Theranostics. 2019 May 26;9(12):3541-3554. doi: 10.7150/thno.32908. eCollection 2019.

2.

Up-regulation of Polo-like Kinase 1 in nasopharyngeal carcinoma tissues: a comprehensive investigation based on RNA-sequencing, gene chips, and in-house tissue arrays.

Yang X, Mo W, Fang Y, Wei G, Wei M, Dang Y, Chen G, Hu K, Wei D.

Am J Transl Res. 2018 Dec 15;10(12):3924-3940. eCollection 2018.

3.

Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.

Xiao D, Yue M, Su H, Ren P, Jiang J, Li F, Hu Y, Du H, Liu H, Qing G.

Mol Cell. 2016 Nov 3;64(3):493-506. doi: 10.1016/j.molcel.2016.09.016. Epub 2016 Oct 20.

4.

Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor.

Alimova I, Pierce AM, Harris P, Donson A, Birks DK, Prince E, Balakrishnan I, Foreman NK, Kool M, Hoffman L, Venkataraman S, Vibhakar R.

Oncotarget. 2017 Oct 19;8(57):97290-97303. doi: 10.18632/oncotarget.21932. eCollection 2017 Nov 14.

5.

Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.

Ferrarotto R, Goonatilake R, Yoo SY, Tong P, Giri U, Peng S, Minna J, Girard L, Wang Y, Wang L, Li L, Diao L, Peng DH, Gibbons DL, Glisson BS, Heymach JV, Wang J, Byers LA, Johnson FM.

Clin Cancer Res. 2016 Apr 1;22(7):1674-1686. doi: 10.1158/1078-0432.CCR-14-2890. Epub 2015 Nov 23.

6.

FBXO32 suppresses breast cancer tumorigenesis through targeting KLF4 to proteasomal degradation.

Zhou H, Liu Y, Zhu R, Ding F, Wan Y, Li Y, Liu Z.

Oncogene. 2017 Jun 8;36(23):3312-3321. doi: 10.1038/onc.2016.479. Epub 2017 Jan 9.

7.

Loss of cytoplasmic KLF4 expression is correlated with the progression and poor prognosis of nasopharyngeal carcinoma.

Liu Z, Yang H, Luo W, Jiang Q, Mai C, Chen Y, Zhen Y, Yu X, Long X, Fang W.

Histopathology. 2013 Sep;63(3):362-70. doi: 10.1111/his.12176. Epub 2013 Jun 12.

PMID:
23758499
8.

PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.

Tan J, Li Z, Lee PL, Guan P, Aau MY, Lee ST, Feng M, Lim CZ, Lee EY, Wee ZN, Lim YC, Karuturi RK, Yu Q.

Cancer Discov. 2013 Oct;3(10):1156-71. doi: 10.1158/2159-8290.CD-12-0595. Epub 2013 Jul 25.

9.

Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.

Ding Y, Huang D, Zhang Z, Smith J, Petillo D, Looyenga BD, Feenstra K, Mackeigan JP, Furge KA, Teh BT.

Cancer Res. 2011 Aug 1;71(15):5225-34. doi: 10.1158/0008-5472.CAN-11-0076. Epub 2011 Jun 3.

10.

In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.

Van den Bossche J, Deben C, De Pauw I, Lambrechts H, Hermans C, Deschoolmeester V, Jacobs J, Specenier P, Pauwels P, Vermorken JB, Peeters M, Lardon F, Wouters A.

Mol Oncol. 2019 May;13(5):1196-1213. doi: 10.1002/1878-0261.12477. Epub 2019 Apr 5.

11.

Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia.

Kannan S, Aitken MJL, Herbrich SM, Golfman LS, Hall MG, Mak DH, Burks JK, Song G, Konopleva M, Mullighan CG, Chandra J, Zweidler-McKay PA.

Mol Cancer Ther. 2019 Sep;18(9):1615-1627. doi: 10.1158/1535-7163.MCT-18-0706. Epub 2019 Jun 21.

PMID:
31227645
12.

Phosphorylation by polo-like kinase 1 induces the tumor-suppressing activity of FADD.

Jang MS, Lee SJ, Kim CJ, Lee CW, Kim E.

Oncogene. 2011 Jan 27;30(4):471-81. doi: 10.1038/onc.2010.423. Epub 2010 Oct 4.

PMID:
20890306
13.

Down-regulation of Sp1 suppresses cell proliferation, clonogenicity and the expressions of stem cell markers in nasopharyngeal carcinoma.

Zhang JP, Zhang H, Wang HB, Li YX, Liu GH, Xing S, Li MZ, Zeng MS.

J Transl Med. 2014 Aug 7;12:222. doi: 10.1186/s12967-014-0222-1.

14.

Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor.

Van den Bossche J, Lardon F, Deschoolmeester V, De Pauw I, Vermorken JB, Specenier P, Pauwels P, Peeters M, Wouters A.

Med Res Rev. 2016 Jul;36(4):749-86. doi: 10.1002/med.21392. Epub 2016 May 3. Review.

PMID:
27140825
15.

Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.

Lee C, Fotovati A, Triscott J, Chen J, Venugopal C, Singhal A, Dunham C, Kerr JM, Verreault M, Yip S, Wakimoto H, Jones C, Jayanthan A, Narendran A, Singh SK, Dunn SE.

Stem Cells. 2012 Jun;30(6):1064-75. doi: 10.1002/stem.1081.

17.

LPLUNC1 inhibits nasopharyngeal carcinoma cell growth via down-regulation of the MAP kinase and cyclin D1/E2F pathways.

Yang Y, Liao Q, Wei F, Li X, Zhang W, Fan S, Shi L, Li X, Gong Z, Ma J, Zhou M, Xiang J, Peng S, Xiang B, Deng H, Yang Y, Li Y, Xiong W, Zeng Z, Li G.

PLoS One. 2013 May 1;8(5):e62869. doi: 10.1371/journal.pone.0062869. Print 2013. Erratum in: PLoS One. 2013;8(8). doi:10.1371/annotation/e120c2f3-efb3-4bac-931d-b53751136785.

18.

XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem Cells.

Ji J, Yu Y, Li ZL, Chen MY, Deng R, Huang X, Wang GF, Zhang MX, Yang Q, Ravichandran S, Feng GK, Xu XL, Yang CL, Qiu MZ, Jiao L, Yang D, Zhu XF.

Theranostics. 2018 Feb 5;8(6):1494-1510. doi: 10.7150/thno.21717. eCollection 2018.

19.

Klf4 reduces stemness phenotype, triggers mesenchymal-epithelial transition (MET)-like molecular changes, and prevents tumor progression in nasopharygeal carcinoma.

Li X, Zhao Z, Zhang X, Yang S, Lin X, Yang X, Lin X, Shi J, Wang S, Zhao W, Li J, Gao F, Liu M, Ma N, Luo W, Yao K, Sun Y, Xiao S, Xiao D, Jia J.

Oncotarget. 2017 Sep 27;8(55):93924-93941. doi: 10.18632/oncotarget.21370. eCollection 2017 Nov 7.

20.

A selective inhibitor of the Polo-box domain of Polo-like kinase 1 identified by virtual screening.

Abdelfatah S, Berg A, Böckers M, Efferth T.

J Adv Res. 2018 Oct 31;16:145-156. doi: 10.1016/j.jare.2018.10.002. eCollection 2019 Mar.

Supplemental Content

Support Center